Ken Griffin Silence Therapeutics PLC Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of SLN stock, worth $2,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500
Previous 300
66.67%
Holding current value
$2,500
Previous $5,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SLN
# of Institutions
66Shares Held
24.6MCall Options Held
500Put Options Held
5K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$15.2 Million3.41% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$14.2 Million0.86% of portfolio
-
Redmile Group, LLC San Francisco, CA2.4MShares$12 Million1.29% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.86MShares$9.28 Million1.01% of portfolio
-
Morgan Stanley New York, NY1.66MShares$8.32 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $179M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...